IPSU

Key Product Details

Product Description

OX₂ receptor antagonist. Exhibits approximately six-fold selectivity for OX₂ versus OX₁ receptors. Decreases activity and increases sleep time in mice during the active phase, without affecting REM/NREM balance. Orally bioavailable. Brain penetrant.

Product Specifications for IPSU

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for IPSU

The following data is based on the product molecular weight 405.49.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.47 mL	12.33 mL	24.66 mL
5 mM	0.49 mL	2.47 mL	4.93 mL
10 mM	0.25 mL	1.23 mL	2.47 mL
50 mM	0.05 mL	0.25 mL	0.49 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Betschart Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J.Med.Chem. 2013 PMID: 23964859
• Hoyer Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front.Neurosci. 2013 PMID: 24376396

Product Documents for IPSU